Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands

(2020) Avinash G Dinmohamed et al.   LANCET ONCOLOGY

Cancer diagnostic rates during the 2020 ‘lockdown’, due to COVID-19 pandemic, compared with the 2018–2019: an audit study from cellular pathology

(2020) Ludovica De Vincentiis et al.   JOURNAL OF CLINICAL PATHOLOGY

Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study

(2020) Amit Sud et al.   LANCET ONCOLOGY

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

(2020) Camille Maringe et al.   LANCET ONCOLOGY

Estimation of COVID-19 spread curves integrating global data and borrowing information

(2020) Se Yoon Lee et al.   PLoS One

COVID-19 and cancer

(2020) Norman E. Sharpless   SCIENCE

ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer

(2020) Loredana Vecchione et al.   ESMO Open

Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic

(2020) Harvey W. Kaufman et al.   JAMA Network Open

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients

(2020) Xiaojing Xu et al.   BMC CANCER

Consequences of COVID-19 for cancer care — a CRUK perspective

(2020) Emma Greenwood et al.   Nature Reviews Clinical Oncology

Circulating cell-free DNA level predicts all-cause mortality independent of other predictors in the Health 2000 survey

(2020) L. Kananen et al.   Scientific Reports

Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA

(2019) Romain Meddeb et al.   CLINICAL CHEMISTRY

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

(2019) J Hamfjord et al.   ANNALS OF ONCOLOGY

Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study

(2019) Qingying Yan et al.   Future Oncology

Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review

(2018) Kaitlyn K.H. Goey et al.   EUROPEAN JOURNAL OF CANCER

Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection

(2018) Clare Fiala et al.   BMC Medicine

The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers

(2018) Hariti Saluja et al.   Frontiers in Oncology

Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer

(2018) Tao Wei et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

(2017) Ludovic Barault et al.   GUT

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer

(2016) Karen-Lise G. Spindler   ACTA ONCOLOGICA

Origins, structures, and functions of circulating DNA in oncology

(2016) A. R. Thierry et al.   CANCER AND METASTASIS REVIEWS

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care

(2016) S. El Messaoudi et al.   CLINICAL CANCER RESEARCH

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer

(2014) Florent Mouliere et al.   Molecular Oncology

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

(2014) Alain R Thierry et al.   NATURE MEDICINE

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies

(2014) Erik von Elm et al.   International Journal of Surgery

Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study

(2011) B. Chibaudel et al.   ONCOLOGIST